由于新减肥药CagriSema实验效果不及预期,诺和诺德美股盘前跌27%。 据媒体报道,诺德诺德为了保持在减肥药市场的领先地位,正在转向研发新款GLP-1类药物CagriSema,预计至少能实现25%的减重效果,但此次实验结果显示只平均减轻了22.7%的体重。风险提示及免责条款 市场有风险,投资需谨慎。本文不构成个人投资建议,也未考虑到个别用户特殊的投资目标、财务状况或...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.